The injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appears to increase a woman’s risk of acquiring the sexually transmitted infections chlamydia and gonorrhea by approximately three ...
Expert Rev of Obstet Gynecol. 2010;5(6):673-686. Each year worldwide, over 380,000 women die from pregnancy and pregnancy-related causes. If contraception were made available to unprotected women, ...
DMPA SC does not protect against HIV infection (AIDS) or other sexually transmitted diseases. Injection site reactions such as injection site pain, injection site tenderness, injection site nodules, ...
To compare longitudinal changes in weight, body fat, and ratio of central to peripheral fat mass among first-time depot-medroxyprogesterone acetate (DMPA) users to women using no hormonal ...
Seattle, April 12, 2018--Evidence published today on a new contraceptive option is providing one possible answer to an age-old question in family planning: how to address barriers that make it ...
A new contraceptive option provides a possible answer to an age-old question in family planning: how to address barriers that make it difficult for women to keep using contraception consistently.
A non-governmental research organisation, Akena Plus Health, has dispelled the misconception that the Depot-Medroxyprogesterone Acetate-Sub Cutaneous, an all-in-one contraceptive that puts women in ...
DALLAS, Sept. 3 – Long-term use of a contraceptive injected once every three months impairs the arteries' ability to contract and expand, possibly increasing the risk for heart disease, according to ...
"This is an exciting milestone for women in the United Kingdom, and, potentially, in countries around the world, who might prefer this method of contraception and mode of administration." Pfizer Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback